CD25+CD4+ regulatory t-cells in cancer

Immunologic Research

Volumn 32, Issue 1-3, 2005, Pages 155-168

  Linehan, David C ^a,b   Goedegebuure, Peter S ^a  

^a USA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer immunity; Cancer; Depletion; Foxp3; Regulatory t cells; Suppression; Transforming growth factor

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; BASILIXIMAB; CANCER VACCINE; CD40 LIGAND MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MOLECULAR MARKER; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; VINBLASTINE;

ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BREAST CARCINOMA; CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CELL MATURATION; CELL PROLIFERATION; CELL PROTECTION; CELLULAR IMMUNITY; DENDRITIC CELL; ENTERITIS; HOST; HUMAN; IMMUNOCOMPETENT CELL; INVASIVE CARCINOMA; LEUKEMIA; LYMPHOCYTE COUNT; LYMPHOMA; MELANOMA; MICROENVIRONMENT; MOLECULAR MECHANICS; MYELOMA; NONHUMAN; OBSERVATION; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REGULATOR GENE; REVIEW; SARCOMA; SUPERNATANT; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD4; BREAST NEOPLASMS; CANCER VACCINES; CARCINOMA, DUCTAL, BREAST; DENDRITIC CELLS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE DEPLETION; MICE; MICE, KNOCKOUT; NEOPLASMS; PANCREATIC NEOPLASMS; PHENOTYPE; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 23844472868     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:32:1-3:155     Document Type: Review

References (58)

1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
2. Takahashi T, Kuniyasu Y, Toda M, et al: Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998;10:1969-1980.
3. Shevach EM, McHugh RS, Thornton AM, Piccirillo C, Natarajan K, Margulies DH: Control of autoimmunity by regulatory T cells. Adv Exp Med Biol 2001;490:21-32.
4. Kojima A, Tanaka-Kojima Y, Sakakura T, Nishizuka Y: Spontaneous development of autoimmune thyroiditis in neonatally thymectomized mice. Lab Invest 1976;34:550-557.
5. Stumbles PA, Penhale WJ: IDDM in rats induced by thymectomy and irradiation. Diabetes 1993;42:571-578.
6. Kontani K, Taguchi O, Takahashi T: Involvement of the H+/K(+)-ATPase alpha subunit as a major antigenic protein in autoimmune gastritis induced by neonatal thymectomy in mice. Clin Exp Immunol 1992;89:63-67.
7. Kojima A, Sakakura T, Tanaka Y, Nishizuka Y: Sterility in neonatally thymectomized female mice: its nature and prevention by the injection of spleen cells. Biol Reprod 1973;8:358-361.
8. Green EA, Choi Y, Flavell RA: Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 2002;16:183-191.
9. Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA: CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA 2003;100:10,878-10,883.
10. Malmstrom V, Shipton D, Singh B, et al: CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J Immunol 2001;166:6972-6981.
11. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061.
12. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336.
13. Thornton AM, Shevach EM: Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000;164:183-190.
14. Walker LS, Chodos A, Eggena M, Dooms H, Abbas AK: Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 2003;198:249-258.
15. Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA: A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 2001;166:7282-7289.
16. Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A: Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol 2002;3:33-41.
17. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135-142.
18. Stephens LA, Mottet C, Mason D, Powrie F: Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 2001;31:1247-1254.
19. Piccirillo CA, Shevach EM: Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167:1137-1140.
20. Azuma T, Takahashi T, Kunisato A, Kitamura T, Hirai H: Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 2003;63:4516-4520.
21. Khattri R, Cox T, Yasayko SA, Ramsdell F: An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003;4:337-342.
22. Bruder D, Probst-Kepper M, Westendorf AM, et al: Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 2004;34:623-630.
23. Mizobuchi T, Yasufuku K, Zheng Y et al: Differential expression of Smad7 transcripts identifies the CD4(+) CD45RC(high) regulatory T cells that mediate type V collagen-induced tolerance to lung allografts. J Immunol 2003;171:1140-1147.
24. Shankaran V, Ikeda H, Bruce AT, et al: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-1111.
25. Smyth MJ, Thia KY, Street SE, et al: Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661-668.
26. Street SE, Hayakawa Y, Zhan Y, et al: Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and {gamma} {delta} T cells. J Exp Med 2004;199:879-884.
27. Pardoll D: Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-839.
28. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998.
29. Woo EY, Yeh H, Chu CS, et al: Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-4276.
30. Woo EY, Chu CS, Goletz TJ, et al: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-4772.
31. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grabeck-Loebenstein B: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-612.
32. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A: CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003;98:1089-1099.
33. Awwad M, North RJ: Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 1989;49:1649-1654.
34. Awwad M, North RJ: Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors. Cancer Res 1990;50:2228-2233.
35. North RJ, Dye ES: Ly 1+2-suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma. Immunology 1985;54:47-56.
36. Rakhmilevich AL, North RJ, Dye ES : Presence of CD4+ T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells. Int J Cancer 1993;55:338-343.
37. Awwad M, North RJ: Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody: a consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity. J Exp Med 1988;168:2193-2206.
38. North RJ, Awwad M: Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 1990;71:90-95.
39. Shimizu J, Yamazaki S, Sakaguchi S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-5218.
40. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999;59:3128-3133.
41. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al: Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194:823-832.
42. Rosenberg SA: Development of effective immunotherapy for the treatment of patients with cancer. J Am Coll Surg 2004;198:685-696.
43. North RJ, Bursuker I: Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2-suppressor T cells down-regulate the generation of Ly-1-2+effector T cells. J Exp Med 1984;159:1295-1311.
44. Liyanage UK, Moore TT, Joo HG, et al: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-2761.
45. Viguier M, Lemaitre F, Verola O, et al: Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-1453.
46. Chen W, Jin W, Hardegen N, et al: Conversion of peripheral CD4+CD25- naïve T cells to CD4+CD25+ regulatory T cells by TGFb induction of transcription factor Foxp3. J Exp Med 2003;198:1875-1886.
47. von Bernstorff W, Voss M, Freichel S, et al: Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 2001;7:925s-932s.
48. Jonuleit H, Schmitt E, Steinbrink K, Enk AH: Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001;22:394-400.
49. Lohr J, Knoechel B, Jiang S, Sharpe AH, Abbas AK: The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol 2003;4:664-669.
50. Yamazaki S, Iyoda T, Tarbell K, et al: Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003;198:235-247.
51. Blattman JN, Greenberg PD: Cancer immunotherapy: a treatment for the masses. Science 2004;305:200-205.
52. Nishikawa H, Kato T, Tanida K, et al: CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 2003;100:10,902-10,906.
53. Wang HY, Lee DA, Peng G, et al: Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004;20:107-118.
54. Wiethe C, Dittmar K, Doan T, Lindenmaier W, Tindle R: Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J Immunol 2003;170:2912-2922.
55. Zheng G, Wang B, Chen A: The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells. J Immunol 2004;173:2428-2434.
56. Awwad M, North RJ: Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour: evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 1988;65:87-92.
57. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-854.
58. Dudley ME, Wunderlich JR, Yang JC, et al: A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002;25:243-251.